Avirmax Biopharma Announces First Patient Dosed in Clinical Trial of ABI-110, a Groundbreaking Gene Therapy for Wet AMD Including PCV
Avirmax Biopharma Announces First Patient Dosed in Clinical Trial of ABI-110, a Groundbreaking Gene Therapy for Wet AMD Including PCV
"Dosing the first patient marks a pivotal step forward in Avirmax's mission to bring transformative gene therapies to patients suffering from severe retinal diseases.," said HAYWARD, Calif., Nov. 21, 2024 /PRNewswire/ -- Avirmax Biopharma, Inc., a leader in the development of innovative gene therapies, today announced that the first patient has been successfully dosed in the Phase I/IIa clinical trial of ABI-110, the company's first gene therapy drug for the treatment of Wet Age-related Macular Degeneration (AMD) including Polypoidal Choroidal Vasculopathy (PCV).
加利福尼亚州海沃德，2024年11月21日 / PRNewswire / - 阿维玛克斯生物制药公司（Avirmax Biopharma, Inc.）是在创新基因治疗领域的领导者，今日宣布该公司针对湿性年龄相关性黄斑变性（AMD）包括多形性脉络膜视网膜病变（PCV）的首个基因治疗药物ABI-110的I / IIa期临床试验已成功为首位患者投药。
"We are thrilled to announce this significant milestone in the clinical investigation of ABI-110" said Shawn Liu, Ph.D., Chief Executive Officer of Avirmax Biopharma Inc. "ABI-110 has the potential to revolutionize the treatment landscape for Wet AMD and PCV."
阿维玛克斯生物制药公司首席执行官刘岄博士表示:"我们很高兴地宣布此重要里程碑的到来，刊登在ABI-110的临床研究中。"ABI-110有潜力革新湿性AMD和PCV的治疗领域。
Avirmax doses first patient in Phase I/IIa trial of ABI-110, a pioneering gene therapy for Wet AMD and PCV
阿维玛克斯首位患者接受ABI-110湿性AMD和PCV I / IIa试验的剂量。
"Dosing the first patient marks a pivotal step forward in Avirmax's mission to bring transformative gene therapies to patients suffering from severe retinal diseases.," said Wendy Murahashi, M.D., Chief Medical Officer of Avirmax Biopharma Inc..
"为首位患者注射剂量标志着阿维玛克斯向重视严重视网膜疾病的患者带来变革性基因治疗使命迈出重要一步。" 阿维玛克斯生物制药公司首席医疗官 Wendy Murahashi 万博士表示。
Wet Age-related Macular Degeneration (AMD) and Polypoidal Choroidal Vasculopathy (PCV) are serious retinal diseases that can lead to severe vision loss. Current treatments often require frequent injections and provide only temporary relief. ABI-110 has the potential to offer a more durable and effective solution by addressing the root causes of these conditions at the genetic level.
湿性年龄相关性黄斑变性（AMD）和多形性脉络膜视网膜病变（PCV）是严重的视网膜疾病，可能导致严重视力损失。目前的治疗通常需要频繁注射，仅提供暂时缓解。 ABI-110有可能通过在基因水平上处理这些病症的根本原因，提供更持久有效的解决方案。
ABI-110, Avirmax Biopharma's proprietary gene therapy, utilizes an engineered capsid, AAV2.N54, to efficiently deliver therapeutic transgene to the macular retina. This approach aims to provide a long-lasting solution that goes beyond the limitations of current treatments. The Phase 1 clinical trial is designed to evaluate the safety, tolerability, and preliminary efficacy of ABI-110 in patients with Wet AMD and PCV.
Avirmax生物制药公司的专有基因治疗ABI-110利用经过改良的载体AAV2.N54，有效将治疗性基因输送到黄斑视网膜。这一方法旨在提供超越当前治疗局限的长期解决方案。I期临床试验旨在评估ABI-110在湿性AMD和PCV患者中的安全性、耐受性和初步疗效。
About Avirmax Biopharma
关于阿维玛克斯生物制药
Avirmax Biopharma Inc., based in the San Francisco Bay Area, is a clinical stage biopharmaceutical company specializing in developing next-generation gene therapies for wet AMD, PCV, geographic atrophy (GA), dry AMD, glaucoma and diabetic retinopathy. Utilizing proprietary AAV vector technologies, Avirmax Biopharma aims to deliver safe, effective, and accessible gene therapies to improve patient outcomes and preserve vision. Visit us at for more information.
总部位于旧金山湾区的Avirmax生物制药公司是一家临床阶段生物制药公司，专门致力于开发下一代基因治疗技术，用于治疗濕性年龄相关性黄斑变性、脉络膜新生血管、地理性萎缩症、干性年龄相关性黄斑变性、青光眼和糖尿病性视网膜病变。Avirmax生物制药公司利用专有的AAV载体技术，旨在提供安全、有效且可获得的基因治疗，改善患者预后并保持视力。欲了解更多信息，请访问我们的网站。
Contact
联系方式
June Song, Associate Director for Operations
Email: [email protected]
Tel: +1-510-641-0201
运营副总监宋君
电子邮件: [email protected]
电话: +1-510-641-0201
Address
25503 Whitesell Street
Hayward 94545 CA
USA
地址
25503 Whitesell街
加利福尼亚州海沃德市94545
美国
SOURCE Avirmax
来源 Avirmax
